Trastuzumab immunogenicity development in patients’ sera and in laboratory animals

BACKGROUND: Immunogenicity is a major challenge in drug development and patient care. Clinicians and regulators are familiar with immunogenicity concerns of monoclonal antibody (mAb) therapeutics, growth factors and enzyme replacements. Although most small therapeutic molecules are unlikely to trigg...

Descripción completa

Detalles Bibliográficos
Autores principales: Kilany, Lobna Abdel Aziz, Gaber, Ayman Abdel Samie, Aboulwafa, Mohammad Mabrouk, Zedan, Hamdallah Hafez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893875/
https://www.ncbi.nlm.nih.gov/pubmed/33607941
http://dx.doi.org/10.1186/s12865-021-00405-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893875/
https://www.ncbi.nlm.nih.gov/pubmed/33607941
http://dx.doi.org/10.1186/s12865-021-00405-z

Ejemplares similares